专注于创新药自主研发的生物医药企业必贝特拟于科创板IPO上市

Core Points - The company, Bibet (688759.SH), has released its prospectus for an initial public offering (IPO) on the Sci-Tech Innovation Board, planning to issue 90 million shares, which will account for approximately 20.00% of the total share capital post-issuance [1] - The IPO will consist entirely of new shares, with no existing shareholders selling shares [1] - The initial strategic placement will involve 18 million shares, representing 20.00% of the total issuance, with final placement amounts to be determined after the pricing on October 15, 2025 [1] Company Overview - Bibet is a biopharmaceutical company focused on innovative drug development, particularly in the fields of oncology, autoimmune diseases, and metabolic diseases [1] - The company aims to develop First-in-Class drugs and innovative medications to meet unmet clinical needs, emphasizing independent innovation and global intellectual property rights [1] Research Pipeline - As of the signing date of the prospectus, the company has one Class 1 innovative drug, BEBT-908, approved for market, while BEBT-209 is in Phase III clinical trials, and BEBT-109 has been approved to start Phase III trials [2] - Five additional products are currently in Phase I clinical trials [2] Fund Utilization - The net proceeds from the IPO, after deducting issuance costs, will be allocated as follows: 949 million yuan for new drug research and development projects, 555 million yuan for the construction of a research and development center and formulation industrialization base in Qingyuan, and 500 million yuan for working capital [2]